InvestSMART

AFT Pharmaceuticals Limited (ASX: AFP) - Announcements

- Current share price for AFP : $3.620

ASX company news and announcements for AFT Pharmaceuticals Limited (AFP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All AFT Pharmaceuticals Limited (AFP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than AFT Pharmaceuticals Limited (AFP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for AFT Pharmaceuticals Limited (AFP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$380 AFT reports double digit growth in 1H FY27 and R&D progress 6 Oct 2026 7:30AM $3.500 $3.620 risen by 3.43%
$380 Maxigesic IV Licensed for Japan 28 Sep 2026 7:31AM $3.480 $3.620 risen by 4.02%
$380 Results of Meeting 31 Jul 2026 1:19PM $4.100 $3.620 fallen by 11.71%
$380 AFT Chair David Flacks to retire before the next ASM 31 Jul 2026 7:30AM $4.000 $3.620 fallen by 9.50%
$380 Annual Meeting Presentation 2026 31 Jul 2026 7:30AM $4.000 $3.620 fallen by 9.50%
$380 Chair's Address to Shareholders 31 Jul 2026 7:30AM $4.000 $3.620 fallen by 9.50%
$380 AFT R&D portfolio offers multi-$bn dollar market potential 28 Jul 2026 7:30AM $3.570 $3.620 risen by 1.40%
$380 AFT R&D portfolio offers multi-$bn market potential 28 Jul 2026 7:30AM $3.570 $3.620 risen by 1.40%
$380 Pitt St Research initiates coverage on AFT Pharmaceuticals 24 Jul 2026 7:54AM $3.290 $3.620 risen by 10.03%
$380 Scomara Tentative Approval by US FDA 21 Jul 2026 9:00AM $3.290 $3.620 risen by 10.03%
$380 AFT reports ongoing sales growth and R&D progress 7 Jul 2026 7:30AM $3.040 $3.620 risen by 19.08%
$380 Notice of Annual Meeting of Shareholders 2026 2 Jul 2026 3:17PM $3.010 $3.620 risen by 20.27%
$380 Update - Dividend/Distribution - AFP 24 Jun 2026 1:54PM $3.040 $3.620 risen by 19.08%
$380 FDA allows AFT injectable iron project clinical study 24 Jun 2026 7:31AM $3.010 $3.620 risen by 20.27%
$380 FDA allows AFT injectable iron project clinical study 24 Jun 2026 7:31AM $3.010 $3.620 risen by 20.27%
$380 Application for quotation of securities - AFP 22 Jun 2026 8:13AM $3.010 $3.620 risen by 20.27%
$380 Capital Change Notice 22 Jun 2026 7:57AM $3.010 $3.620 risen by 20.27%
$380 Update - Dividend/Distribution - AFP 26 May 2026 7:33AM $3.030 $3.620 risen by 19.47%
$380 Annual Meeting and Closing Date for Director Nominations 25 May 2026 7:32AM $3.050 $3.620 risen by 18.69%
$380 Dividend/Distribution - AFP 22 May 2026 1:16PM $3.050 $3.620 risen by 18.69%
$380 Issue of unlisted options 22 May 2026 8:30AM $3.050 $3.620 risen by 18.69%
$380 Dividend distribution update 21 May 2026 10:07AM $2.930 $3.620 risen by 23.55%
$380 FY26 NZX App2 21 May 2026 7:31AM $2.860 $3.620 risen by 26.57%
$380 FY26 Annual Report 21 May 2026 7:30AM $2.860 $3.620 risen by 26.57%
$380 FY26 results presentation 21 May 2026 7:30AM $2.860 $3.620 risen by 26.57%

1 - 25 of 548 results

Page 1 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.